BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Myelofibrosis and MPNs clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for myelofibrosis: 61 (35 sponsors; 6 newly posted in the last 180 days, 5 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 10.7, rank 63 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 24, Phase 2 18, Phase 3 13, Phase 4 1, N/A 5.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Novartis Pharmaceuticals NVS4P3 2, P4 1, P1 100
Celgene2P3 200
Chengdu Zenitar Biomedical Technology Co., Ltd4P3 1, P2 310
AbbVie ABBV3P1 2, P3 102
Karyopharm Therapeutics Inc KPTIQ3P3 1, P2 200
Geron Corporation GERN2P1 1, P3 101
Swedish Orphan Biovitrum2P3 1, NA 111
Takeda TAK2P2 1, P3 110
Kartos Therapeutics, Inc.1P3 101
Merck Sharp & Dohme LLC MRK1P3 100
PharmaEssentia1P3 100
Incyte Corporation INCY6P1 601
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.5P1 3, P2 223
Bristol-Myers Squibb BMY2P2 1, NA 100
GlaxoSmithKline2P2 202
iOnctura2P1 1, P2 100
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company1P1 100
Aspera Biomedicines, Inc.1P1 100
Cellenkos, Inc.1P1 101
CERo Therapeutics Holdings, Inc. CERO1P1 101
Chiesi Farmaceutici S.p.A.1NA 100
Damora Therapeutics DMRA new entrant1P1 110
Disc Medicine, Inc IRON1P2 101
Eilean Therapeutics1P1 100
Eilean Therapeutics AU Pty Ltd1P1 100

New-entrant sponsors: Damora Therapeutics.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2ItalfarmacoNCT01761968 Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsChronic Myeloproliferative Neoplasmsactive not recruiting90
2026-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06122831 A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)Myelofibrosisrecruiting92
2026-12-11 est.P2GlaxoSmithKlineNCT03441113 Extended Access of Momelotinib in Adults With MyelofibrosisPrimary Myelofibrosisactive not recruiting237
2026-12-31 est.P3Kartos Therapeutics, Inc.NCT06479135 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibMyelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MFrecruiting600

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-05 est.P3Swedish Orphan BiovitrumNCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibactive not recruiting407
2026-09 est.P1/P2Silence Therapeutics plc SLNNCT05499013 Study to Assess SLN124 in Patients With Polycythemia VeraPolycythemia Veraactive not recruiting69
2026-09 est.P2Karyopharm Therapeutics Inc KPTIQNCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisactive not recruiting112
2026-07 est.P3ItalfarmacoNCT06093672 Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraPolycythemia Verarecruiting220
2026-06-30P2Ryvu Therapeutics SANCT06397313 RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisMyelofibrosisterminated36
2026-06-30 est.P3PharmaEssentia Japan K.K.NCT04655092 Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsPolycythemia Vera (PV)recruiting67

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myelofibrosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.